Abstract
Innovative anticancer strategies have contributed to an improved survival of patients suffering from malignancies, and in some cases, have turned cancer into a chronic disease. Therefore, the early and particularly late onsets of adverse cardiovascular effects of systemic anticancer treatments are of increasing interest. Among a rapidly increasing variety of anticancer drugs, the anthracyclines and the monoclonal antibody, trastuzumab, are the agents with a well-known cardiotoxicity. The diagnostic work-up, the cardiotoxic risk of anthracyclines and trastuzumab, and additionally, cardiotoxicity as a risk factor of a multimodal therapeutic approach in breast cancer patients is discussed in this study.
MeSH terms
-
Animals
-
Anthracyclines / adverse effects
-
Anthracyclines / toxicity
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / toxicity
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Agents / toxicity
-
Atrial Natriuretic Factor / blood
-
Cardiotoxins / adverse effects*
-
Cardiotoxins / toxicity
-
Heart / drug effects*
-
Heart Failure / blood
-
Heart Failure / diagnosis
-
Heart Injuries / chemically induced
-
Heart Injuries / epidemiology
-
Humans
-
Radiation Injuries / epidemiology
-
Radiotherapy / adverse effects
-
Trastuzumab
Substances
-
Anthracyclines
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Cardiotoxins
-
Atrial Natriuretic Factor
-
Trastuzumab